Savolitinib

Lung cancer is a leading cause of cancer death globally, with EGFRm NSCLC patients particularly sensitive to EGFR-TKI treatment. LAURA trial assessed Tagrisso in Stage III EGFRm NSCLC patients post-CRT, enrolling 216 patients across 15 countries. Tagrisso, a third-generation EGFR-TKI, has demonstrated efficacy in various NSCLC stages and is being explored in early-stage and resistant settings. AstraZeneca aims to improve lung cancer outcomes through early detection and innovative treatments.

Final results of the phase II SWOG 1500 trial showed no significant overall survival benefit with cabozantinib vs sunitinib in advanced papillary renal cell carcinoma patients, despite cabozantinib's improvement in progression-free survival and objective response rate.

TROPION-Lung01 trial results show datopotamab deruxtecan (12.9 months OS) vs. docetaxel (11.8 months OS) in overall population, with nonsquamous histology showing 14.6 months vs. 12.3 months OS. In patients with actionable genomic alterations, datopotamab deruxtecan showed 15.6 months OS compared to 9.8 months with docetaxel. NeoCOAST-2 trial preliminary results indicate 34.1% pCR and 65.9% mPR with datopotamab deruxtecan plus Imfinzi and carboplatin in early-stage NSCLC.

HUTCHMED announces new data from studies of compounds to be presented at 2024 WCLC and ESMO Congresses. Key findings include positive results from the FLOWERS study, showing deeper and more durable response with osimertinib plus savolitinib in EGFRm, MET-aberrant advanced NSCLC patients compared to osimertinib monotherapy.

Laurence Albiges discussed effective treatments for various non–clear cell renal cell carcinoma (nccRCC) subtypes at the 2024 Kidney Cancer Research Summit. Treatments include combinations like cabozantinib/nivolumab for papillary RCC, lenvatinib/pembrolizumab for chromophobe RCC, and immuno-oncology plus tyrosine kinase inhibitor for translocation RCC. Challenges include small patient numbers and the need for more data on adjuvant strategies.